Livongo and Voluntis Partner to Deliver Insulin Titration App

Livongo Members with Type 2 Diabetes Will Get Voluntis’ Insulia®

Cambridge, MA; and Mountain View, CA: February 15, 2017 – Livongo Health and Voluntis announced today a partnership to offer the Livongo for Diabetes program with Voluntis’ Insulia®, an FDA-cleared medical device and app that provides basal insulin dose recommendations for people with Type 2 diabetes. Livongo is the leading consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives and Voluntis innovates healthcare by embedding connectivity in therapeutics and medical intelligence in software. With this alliance, Livongo and Voluntis will create an expanded solution that aims to improve medication adherence and optimization by offering better information personalized to Livongo members.

The Livongo for Diabetes program is a proven approach to diabetes management that includes a cellular-enabled blood glucose meter that provides personal insights driven by data science, unlimited checking supplies for members, and 24×7 coaching based on actual real-time blood sugar and patient information. Insulia®, which is prescribed by the member’s healthcare provider, delivers automated basal insulin dose recommendations and educational coaching messages to people with diabetes through a smartphone app. The combination of these solutions will provide better information leading to medication optimization for Livongo members. Livongo Certified Diabetes Educators will be able to leverage additional information collected from Insulia® to further optimize their recommendations and insights to make diabetes management easier for people with Type 2 diabetes and their providers.

About 95% of people with diabetes have Type 2 diabetes[1], a chronic condition that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. While lifestyle plays an important role in Type 2 diabetes, managing the chronic condition is more complex than just weight loss and nutrition. For those who have been prescribed insulin, studies have indicated that less than 50% of patients achieve the glycemic goals recommended by the American Diabetes Association[2]. Studies also show that people trying to better control their blood sugar are likely to benefit from insulin dosing algorithms[3], which could make starting on insulin and getting to the optimal dose a much faster and smoother process.

Medication optimization is important because suboptimal medication use can lead to poor health outcomes and medication is a large cost driver of diabetes, the most expensive healthcare condition in the US[4]. Improving medication adherence through the use of insulin dosing algorithms and personalized coaching can offer better health outcomes and cost savings for consumers, payers, and providers.

“We know that the three pillars of diabetes management are nutrition, exercise, and medication,” said Dr. Jennifer Schneider, Chief Medical Officer of Livongo. “But having the right information on how to manage is also critical.  By integrating with Insulia®, we can give members with Type 2 diabetes additional insight and tips for medication optimization – making managing diabetes easier.”

“We are pleased to be bringing Insulia® to Livongo members,” said Romain Marmot, Chief Operations Officer of Voluntis. “Livongo’s mission to empower patients through technology is in perfect accord with our own. We hope that by combining Insulia® companion software with Livongo’s diabetes program we can further empower people living with Type 2 diabetes.”

The Livongo for Diabetes program is available through a growing number of the country’s most progressive self-insured employers, leading Fortune 500 companies, health plans, and health systems with tens of thousands of people with diabetes enrolled today. Voluntis will launch Insulia® throughout the United States in 2017.

About Livongo Health

Livongo is the leading consumer digital health company that empowers people with chronic conditions to live a better life. We have developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights and support to make diabetes management easier. Our approach is leading to better clinical and financial outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. For more information visit: View and download Livongo’s latest images for media use at

About Voluntis

Pioneering therapeutic companion software, Voluntis innovates healthcare by embedding connectivity in therapeutics and medical intelligence in software. Dedicated to managing chronic conditions, Voluntis’ companion software aims to enable treatment personalization, to support team-care coordination and to improve real-world outcomes. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, cancer, anticoagulation treatments and hemophilia. Voluntis is headquartered in Paris, France, and has offices in Cambridge, MA. For more information, visit Insulia® is powered by Voluntis proprietary technology platform Theraxium® that ensures data privacy and security, processes workflows and analytics, and enables interoperability with other IT platforms and devices.

[1] Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014.

[2] Bailey CJ, Kodack M. “Patient adherence to medication requirements for therapy of type 2 diabetes.”

Int J Clin Pract. 2011 Mar; 65(3):314-22.

[3]Arnolds, S. Common Standards of Basal Insulin Titration in T2DM, J Diabetes Sci Technol. 2013 May; 7(3): 771–788.

[4] Dieleman, J.L. (2016). US Spending on Personal Health Care and Public Health, 1996-2013. JAMA, 316(24):2627-2646. doi:10.1001/jama.2016.16885